228 related articles for article (PubMed ID: 23949153)
1. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study.
McCowan C; Wang S; Thompson AM; Makubate B; Petrie DJ
Br J Cancer; 2013 Sep; 109(5):1172-80. PubMed ID: 23949153
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
3. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
4. The benefits and costs of tamoxifen for breast cancer prevention.
Eckermann SD; Martin AJ; Stockler MR; Simes RJ
Aust N Z J Public Health; 2003; 27(1):34-40. PubMed ID: 14705265
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Imai H; Kuroi K; Ohsumi S; Ono M; Shimozuma K
Breast Cancer; 2007; 14(1):81-7. PubMed ID: 17245000
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
8. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality.
Makubate B; Donnan PT; Dewar JA; Thompson AM; McCowan C
Br J Cancer; 2013 Apr; 108(7):1515-24. PubMed ID: 23519057
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database.
Yang JJ; Park SK; Cho LY; Han W; Park B; Kim H; Lee KS; Hahn SK; Cho SI; Ahn SH; Noh DY;
Clin Ther; 2010 Jun; 32(6):1122-38. PubMed ID: 20637966
[TBL] [Abstract][Full Text] [Related]
12. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Karnon J; Delea T; Barghout V
Eur J Health Econ; 2008 May; 9(2):171-83. PubMed ID: 17602251
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.
van Nuland M; Vreman RA; Ten Ham RMT; de Vries Schultink AHM; Rosing H; Schellens JHM; Beijnen JH; Hövels AM
Breast Cancer Res Treat; 2018 Nov; 172(1):143-150. PubMed ID: 30006796
[TBL] [Abstract][Full Text] [Related]
14. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.
Risebrough NA; Verma S; Trudeau M; Mittmann N
Cancer; 2007 Aug; 110(3):499-508. PubMed ID: 17592825
[TBL] [Abstract][Full Text] [Related]
16. Cancer Care Coordinators to Improve Tamoxifen Persistence in Breast Cancer: How Heterogeneity in Baseline Prognosis Impacts on Cost-Effectiveness.
Nair N; Kvizhinadze G; Blakely T
Value Health; 2016 Dec; 19(8):936-944. PubMed ID: 27987643
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.
Thompson D; Taylor DC; Montoya EL; Winer EP; Jones SE; Weinstein MC
Value Health; 2007; 10(5):367-76. PubMed ID: 17888101
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
Rocchi A; Verma S
Support Care Cancer; 2006 Sep; 14(9):917-27. PubMed ID: 16596419
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
Moeremans K; Annemans L
Int J Gynecol Cancer; 2006; 16 Suppl 2():576-8. PubMed ID: 17010076
[TBL] [Abstract][Full Text] [Related]
20. Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer.
Thomas RJ; Williams M; Glen J; Callam M
Breast Cancer Res Treat; 2009 Sep; 117(2):289-95. PubMed ID: 19122976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
